680 related articles for article (PubMed ID: 24347111)
21. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
22. Associations between Single Nucleotide Polymorphisms in the Mitochondrial DNA D-Loop Region and Outcome of Gastroenteropancreatic Neuroendocrine Neoplasm.
Er LM; Li Y; Er L; Wu M; Zheng XL; Guo ZJ; Yuan HF
Ann Clin Lab Sci; 2018 May; 48(3):333-337. PubMed ID: 29970437
[TBL] [Abstract][Full Text] [Related]
23. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
[TBL] [Abstract][Full Text] [Related]
24. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing.
Panarelli N; Tyryshkin K; Wong JJM; Majewski A; Yang X; Scognamiglio T; Kim MK; Bogardus K; Tuschl T; Chen YT; Renwick N
Endocr Relat Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 30021866
[TBL] [Abstract][Full Text] [Related]
25. Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.
Berardi R; Torniai M; Partelli S; Rubini C; Pagliaretta S; Savini A; Polenta V; Santoni M; Giampieri R; Onorati S; Barucca F; Murrone A; Bianchi F; Falconi M
PLoS One; 2018; 13(5):e0197035. PubMed ID: 29787601
[TBL] [Abstract][Full Text] [Related]
26. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
27. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
[TBL] [Abstract][Full Text] [Related]
28. Lymph Node Metastasis in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors.
Martin JA; Warner RRP; Aronson A; Wisnivesky JP; Kim MK
Pancreas; 2017 Oct; 46(9):1214-1218. PubMed ID: 28902794
[TBL] [Abstract][Full Text] [Related]
29. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
[TBL] [Abstract][Full Text] [Related]
30. DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors.
Rahman MM; Qian ZR; Wang EL; Yoshimoto K; Nakasono M; Sultana R; Yoshida T; Hayashi T; Haba R; Ishida M; Okabe H; Sano T
Hum Pathol; 2010 Aug; 41(8):1069-78. PubMed ID: 20381114
[TBL] [Abstract][Full Text] [Related]
31. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
[TBL] [Abstract][Full Text] [Related]
32. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors.
Pelosi G; Bianchi F; Dama E; Metovic J; Barella M; Sonzogni A; Albini A; Papotti M; Gong Y; Vijayvergia N
Endocr Pathol; 2021 Sep; 32(3):396-407. PubMed ID: 33433886
[TBL] [Abstract][Full Text] [Related]
33. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
34. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
[TBL] [Abstract][Full Text] [Related]
35. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
36. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L
Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
[TBL] [Abstract][Full Text] [Related]
37. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
38. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study.
Gudmundsdottir H; Möller PH; Jonasson JG; Björnsson ES
Scand J Gastroenterol; 2019 Jan; 54(1):69-75. PubMed ID: 30638086
[TBL] [Abstract][Full Text] [Related]
39. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
[TBL] [Abstract][Full Text] [Related]
40. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
